Schizophrenia Clinical Trial
— INITIATEOfficial title:
A Canadian Non-interventional Study of Aripiprazole Once-Monthly (AOM) Administration in Hospitalized Patients With Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder
NCT number | NCT04907279 |
Other study ID # | 031-203-00468 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 1, 2021 |
Est. completion date | June 2023 |
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its clinical use in the proposed patient population, including time to discharge, efficacy, safety, tolerability, and patients' satisfaction.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | June 2023 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: 1. The patient is between the age of majority (18 or 19 depending on the province) and 64 years of age inclusively; 2. The patient is currently hospitalized for the treatment of schizophrenia, schizoaffective disorder or BP1; 3. The patient is diagnosed with schizophrenia, schizoaffective disorder, or BP1 as defined by DSM-5 criteria; 4. The treating physician reached the decision to treat the patient with AOM prior to and independently of soliciting the patient to participate in the study; 5. The patient initiated treatment with AOM prior to enrolment and in accordance with routine clinical practice, including the assessment of potential risks associated with the medication (e.g. suicidality); 6. The patient or legal guardian (if applicable and when allowable by law) signed an informed consent indicating the understanding of the study and allowing the use of their anonymous data for the purposes of the study; and 7. The patient and caregiver(s) (if applicable) is/are fluent in English or French, in order to be able to complete the patient-administered questionnaires. Exclusion Criteria: 1. As per clinical judgement of the treating physician, the patient is diagnosed with treatment-resistant schizophrenia; 2. The patient does not comprehend or refuses to sign the informed consent; 3. The patient is unlikely to comply with study procedures according to the clinical judgment of the investigator; 4. The patient has any contraindications to the use of AOM as specified in the Canadian Product Monograph; 5. The patient is a member of the study personnel or of their immediate families or is a subordinate (or immediate family member of a subordinate) to any of the study personnel; 6. The patient has previously been enrolled in this study. |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital, Civic Campus | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Otsuka Canada Pharmaceutical Inc. | Lundbeck Canada Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average dose of Aripiprazole Once Monthly (AOM) | The average total dose of AOM administered (number of mg and frequency of administration) during the hospitalization period will be evaluated | Through study completion, an average of 3 weeks | |
Secondary | Duration of hospital stay | Number of days between initiation of AOM and termination of hospital stay | Through study completion, an average of 3 weeks | |
Secondary | Clinical Global Impression-Improvement (CGI-I) score | Mean change in clinical symptom severity from baseline | Through study completion, an average of 3 weeks | |
Secondary | Global Impression-Severity of Illness (CGI-S) score | Mean global severity of clinical symptoms | Through study completion, an average of 3 weeks | |
Secondary | Personal and Social Performance (PSP) score | Mean psycho-social functioning score | Through study completion, an average of 3 weeks | |
Secondary | Medication Satisfaction Questionnaire (MSQ) score | Mean score/level of satisfaction with current treatment administered | Through study completion, an average of 3 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |